Niels Sharman

TQx WILL SHIFT PARADIGMS IN CELL & GENE THERAPY. The TQx platform will transform the traditional way of producing cellular therapies, which is often slow, expensive, and hard to scale, into a very fast and highly automated process right at the patients side. This method uses extra-corporeal gene therapy but keeps the benefits of autologous cell therapy, where patients receive treatments made from their own cells. Our TQx method makes it easier to create genetically modified immune cells (like CAR-T cells) and deliver cell therapy directly to the patient. This avoids the complicated and costly steps of centralized production. As a result, this approach unlocks the full potential of autologous cell therapies for treating conditions that were previously difficult to address, including rare autoimmune diseases and cancers.

With its innovative and comprehensive platform for medical software, Nia Health is helping to reduce the burden and stigmatization of people with chronic skin conditions. The award winning eczema app Nia is the first product of the medical device manufacturer.

InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

C-mo is a wearable cough-monitoring device that provides a comprehensive assessment of cough’s distinctive characteristics. The information provided by C-mo will allow doctors to expand their knowledge base, possess a more comprehensive and objective information set and consequently, to provide more accurate diagnosis and prescribe more tailored treatments.

Ebenbuild is a digital health tech pioneer developing precise, patient-specific simulation models of lungs based on patient data, so-called digital twins of the lungs. Its digital toolset is based on physics-based simulation, AI, and data science and is designed to support decision makers in the life sciences industry, clinicians, and physicians. Ebenbuilds approach provides a better understanding of respiratory diseases and individual pathophysiology enabling a new class of products and services ranging from in silico trials to accelerate and de-risk the development of inhaled drugs to personalized treatment options that improve the chances of survival and recovery in millions of cases of respiratory conditions such as Acute Respiratory Distress Syndrome (ARDS) each year.

Altavo, the artificial voice company. We are a medical device startup based in Dresden, Germany. Our guiding star: harnessing the power of machine learning and state-of-the-art sensor technology to improve the lives of people who have lost their voice. The first group to benefit will be patients who have lost their voice box because of tumor surgery, a procedure known as laryngectomy. But there are many more potential applications of our technology, both in speech rehabilitation and in non-medical fields. We come from different fields: medical device development & marketing, artificial intelligence, RF engineering, signal processing, linguistics & speech therapy, regulatory affairs, and quality management. We share one passion: to turn state-of-the-art technologies into products that improve patients’ quality of life.

LOEWI is powered by bioniq since 2022! We empower people to be the healthiest version of themselves by making personalized health transparent and accessible. We analyze micro- and macronutrients through finger-prick blood tests, visualize the results through a health platform and offer personalized diet recommendations and personalized supplements to match individual needs. Thereby we apply renowned methods of the sports medical examination center in Munich to provide a user-centric and end-to-end concept for our clients. https://bioniq.com/en/linkedin

FundaMental Pharma is engaged in pioneering research around a breakthrough molecular mechanism that allows to safely counteract glutamate neurotoxicity (also known as excitotoxicity) by specifically targeting the interface between NMDA receptors and TRPM4 channels with small molecule TwinF interface inhibitors (Yan et al., Science 2020). TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. Our initial focus is on amyotrophic lateral sclerosis (ALS). The applicability of our molecules extends to a range of neurogenerative disorders including Alzheimer’s disease (AD).

NEOM is a vision of what the future will be at a time when the world needs innovative solutions. It will be a destination and a home for people who dream big and want to participate in building a new model for sustainable living.  #NEOM

TQx WILL SHIFT PARADIGMS IN CELL & GENE THERAPY. The TQx platform will transform the traditional way of producing cellular therapies, which is often slow, expensive, and hard to scale, into a very fast and highly automated process right at the patients side. This method uses extra-corporeal gene therapy but keeps the benefits of autologous cell therapy, where patients receive treatments made from their own cells. Our TQx method makes it easier to create genetically modified immune cells (like CAR-T cells) and deliver cell therapy directly to the patient. This avoids the complicated and costly steps of centralized production. As a result, this approach unlocks the full potential of autologous cell therapies for treating conditions that were previously difficult to address, including rare autoimmune diseases and cancers.

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed approx. 800 start-ups and successfully sold shares in 200 companies. HTGF has over 2 billion euros of fund volume. Fund investors in the public-private partnership include the German Federal Ministry of Economics and Energy, KfW Capital and 45 companies.

With its innovative and comprehensive platform for medical software, Nia Health is helping to reduce the burden and stigmatization of people with chronic skin conditions. The award winning eczema app Nia is the first product of the medical device manufacturer.